Is The Santa Claus Rally The Gift That Keeps Giving?
Remember the horror of 2008 when the Great Recession hit…
Sell
39
VITOF Quote, Financials, Valuation and Earnings
Last price:
$0.66
Seasonality move
:
20.41%
Day range:
$0.66 - $0.66
52-week range:
$0.65 - $1.00
Dividend yield:
0%
P/E ratio:
2.35x
P/S ratio:
0.99x
P/B ratio:
0.46x
Volume:
--
Avg. volume:
--
1-year change:
-34%
Market cap:
$310.2M
Revenue:
$310.7M
EPS (TTM):
--
Analysts' Opinion
-
Consensus RatingVitro SAB de CV has received a consensus rating of --. The company's average rating is a -- based on 0 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target DownsideAccording to analysts' consensus price target of --, Vitro SAB de CV has an estimated downside of -- from its current price of $0.66.
-
Price Target UpsideAccording to analysts, the highest upside price target is -- representing -100% upside increase from its current price of $0.66.
Fair Value
-
According to the consensus of 0 analysts, Vitro SAB de CV has -- downside to fair value with a price target of -- per share.
VITOF vs. S&P 500
-
Over the past 5 trading days, Vitro SAB de CV has underperformed the S&P 500 by -2.86% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Vitro SAB de CV does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Vitro SAB de CV has grown year-over-year revenues for 3 quarters straight. In the most recent quarter Vitro SAB de CV reported revenues of --.
Earnings Growth
-
Vitro SAB de CV has grown year-over-year earnings for 1 quarter straight. In the most recent quarter Vitro SAB de CV reported earnings per share of --.
Enterprise value:
385.1M
EV / Invested capital:
--
Price / LTM sales:
0.99x
EV / EBIT:
2.07x
EV / Revenue:
1.24x
PEG ratio (5yr expected):
0.00x
EV / Free cash flow:
1.36x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
1.73x
Gross Profit (TTM):
--
Return On Assets:
--
Net Income Margin (TTM):
--
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2022-12-31 | 2023-12-31 | |
| Income Statement | ||||||
| Revenue | $2B | $251.6M | $310.3M | -$1.5B | -$1.5B | |
| Gross Profit | $396M | $100.6M | $150.8M | -$302.6M | -$310.8M | |
| Operating Income | -$8M | -$3.8M | $29.9M | -$87.5M | -$93.4M | |
| EBITDA | $114.5M | $208.3M | $223M | $29.6M | $70.3M | |
| Diluted EPS | -$0.24 | $0.05 | $0.28 | $0.02 | $0.09 | |
| Period Ending | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $943.7M | $1.1B | $869.5M | $831.7M | $862.7M | |
| Total Assets | $2.8B | $2.9B | $2.5B | $2.6B | $1.6B | |
| Current Liabilities | $418.3M | $707.2M | $1.1B | $589.4M | $642.9M | |
| Total Liabilities | $1.4B | $1.6B | $1.3B | $1.4B | $965.3M | |
| Total Equity | $1.4B | $1.3B | $1.2B | $1.2B | $672.6M | |
| Total Debt | $661.2M | $864.6M | $682.7M | $702.2M | $112.4M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2022-03-31 | 2023-03-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -- | $5.4M | $315.7M | -$19.7M | $21.5M | |
| Cash From Investing | -- | -$101.4M | -$173.3M | -$23.9M | -$57.5M | |
| Cash From Financing | -- | -$50.4M | -$23.3M | $18.6M | $115.7M | |
| Free Cash Flow | $92.8M | -$103.6M | $283.2M | -$46.9M | -$29.6M | |
VITOF
Sector
Market Cap
$310.2M
$18.9M
Price % of 52-Week High
66%
57.66%
Dividend Yield
0%
0%
Shareholder Yield
--
1.61%
1-Year Price Total Return
-34%
-18.53%
Beta (5-Year)
-19.493
1.064
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Sell
Level
$0.66
200-day SMA
Sell
Level
$0.66
Bollinger Bands (100)
Sell
Level
0.66 - 0.66
Chaikin Money Flow
Buy
Level
419.9K
20-day SMA
Sell
Level
$0.66
Relative Strength Index (RSI14)
Sell
Level
9.20
ADX Line
Neutral
Level
Williams %R
Buy
Level
0
50-day SMA
Sell
Level
$0.66
MACD (12, 26)
Sell
Level
0.00
25-day Aroon Oscillator
Sell
Level
0
On Balance Volume
Neutral
Level
3.9M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (1.1091)
Buy
CA Score
(Annual)
Level (-0.248)
Buy
Beneish M-Score
(Annual)
Level (-3.4822)
Sell
Momentum Score
Level (2)
Buy
Ohlson Score
Level (-0.0359)
Buy
Piotroski F Score
(Annual)
Level (8)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Vitro SAB de CV is a glass manufacturing company. The company is principally engaged in the production, processing, distribution and marketing range of glassware. Its reportable segment includes Flat glass; Chemicals and Glass containers. Flat glass is used for the construction and automotive industries, carbonate and sodium bicarbonate products. Its Glass containers are used in precision components, as well as machinery and molds for the glass industry. The company derives the maximum revenue from the Flat Glass segment. Geographically, it generates a majority of revenue from the USA.
Stock Forecast FAQ
In the current month, VITOF has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The VITOF average analyst price target in the past 3 months is --.
-
Where Will Vitro SAB de CV Stock Be In 1 Year?
According to analysts, the consensus estimate is that Vitro SAB de CV share price will drop to -- per share over the next 12 months.
-
What Do Analysts Say About Vitro SAB de CV?
Analysts are divided on their view about Vitro SAB de CV share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Vitro SAB de CV is a Sell and believe this share price will rise from its current level to --.
-
What Is Vitro SAB de CV's Price Target?
The price target for Vitro SAB de CV over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is VITOF A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Vitro SAB de CV is a --. 0 of 0 analysts rate the stock a -- at this time.
-
How Can I Buy Shares Of VITOF?
You can purchase shares of Vitro SAB de CV via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Vitro SAB de CV shares.
-
What Is The Vitro SAB de CV Share Price Today?
Vitro SAB de CV was last trading at $0.66 per share. This represents the most recent stock quote for Vitro SAB de CV. Yesterday, Vitro SAB de CV closed at $0.66 per share.
-
How To Buy Vitro SAB de CV Stock Online?
In order to purchase Vitro SAB de CV stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Alphabet an Undervalued Growth Stock to Buy?
Alphabet (NASDAQ:GOOGL) is easily one of the most successful companies…
Is Tesla Going to Buy Uber?
Tesla has always been in the habit of making large,…
Stock Ideas
Buy
65
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 42x
Buy
57
Is NVDA Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 118x
Buy
58
Is MSFT Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 37x
Alerts
Buy
87
PSIX alert for Dec 25
Power Solutions International [PSIX] is up 27.42% over the past day.
Buy
65
TSLL alert for Dec 25
Direxion Daily TSLA Bull 2X Shares [TSLL] is up 19.46% over the past day.
Buy
75
SMLR alert for Dec 25
Semler Scientific [SMLR] is up 15.37% over the past day.
